Datar Cancer Genetics UK Private Limited is a specialized medical technology company focused on enhancing cancer care through innovative liquid biopsy solutions. Established in 2019, the company operates as a limited liability company (Ltd) under registration number 12211790. We are dedicated to improving patient outcomes through the application of advanced liquid biopsy technology. Our core service centers around providing personalized, non-invasive cancer care. We leverage sophisticated liquid biopsy analysis to identify and monitor cancer cells, offering a crucial diagnostic and therapeutic pathway. This includes developing and delivering targeted therapies, guiding treatment decisions, and providing continuous monitoring of patient responses. We specialize in the development and validation of liquid biopsy assays, utilizing cutting-edge analytical techniques to detect and characterize cancer biomarkers. Our expertise extends to interpreting these data to inform clinical practice and optimize treatment strategies. We are committed to international collaboration and strategic partnerships within the healthcare sector. Currently, we are operating as a Skilled Worker visa holder, holding a Worker (A rating) visa. We are actively expanding our international presence through strategic collaborations and market penetration. Our focus is on delivering superior patient care through advanced technology.

Datar Cancer Genetics UK Private Limited is a specialized medical technology company focused on enhancing cancer care through innovative liquid biopsy solutions. Established in 2019, the company operates as a limited liability company (Ltd) under registration number 12211790. We are dedicated to improving patient outcomes through the application of advanced liquid biopsy technology. Our core service centers around providing personalized, non-invasive cancer care. We leverage sophisticated liquid biopsy analysis to identify and monitor cancer cells, offering a crucial diagnostic and therapeutic pathway. This includes developing and delivering targeted therapies, guiding treatment decisions, and providing continuous monitoring of patient responses. We specialize in the development and validation of liquid biopsy assays, utilizing cutting-edge analytical techniques to detect and characterize cancer biomarkers. Our expertise extends to interpreting these data to inform clinical practice and optimize treatment strategies. We are committed to international collaboration and strategic partnerships within the healthcare sector. Currently, we are operating as a Skilled Worker visa holder, holding a Worker (A rating) visa. We are actively expanding our international presence through strategic collaborations and market penetration. Our focus is on delivering superior patient care through advanced technology.